KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Cash: 2009-2024

Historic Change in Cash for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to -$248.8 million.

  • Regeneron Pharmaceuticals' Change in Cash rose 495.10% to $497.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $501.3 million, marking a year-over-year increase of 437.80%. This contributed to the annual value of -$248.8 million for FY2024, which is 34.80% up from last year.
  • As of FY2024, Regeneron Pharmaceuticals' Change in Cash stood at -$248.8 million, which was up 34.80% from -$381.6 million recorded in FY2023.
  • Regeneron Pharmaceuticals' 5-year Change in Cash high stood at $690.8 million for FY2021, and its period low was -$381.6 million during FY2023.
  • Its 3-year average for Change in Cash is -$136.4 million, with a median of -$248.8 million in 2024.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Change in Cash soared by 284.41% in 2020 and then slumped by 272.44% in 2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Change in Cash (Yearly) stood at $577.0 million in 2020, then increased by 19.72% to $690.8 million in 2021, then slumped by 67.96% to $221.3 million in 2022, then plummeted by 272.44% to -$381.6 million in 2023, then spiked by 34.80% to -$248.8 million in 2024.